Nasdaq

FDA Approves Ortho Dermatologics' Labeling For JUBLIA® (efinaconazole) Topical Solution, 10%, In Patients As Young As Six Years Old

LAVAL, Quebec, April 29, 2020 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care ...
FierceBiotech

Valeant Pharmaceuticals Announces FDA Approval Of Jublia® for the Treatment of Onychomycosis

LAVAL, Quebec, June 9, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. VRX-0.71% CA:VRX-1.09% today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North ...
Nasdaq

Valeant's Jublia Approved in the U.S. - Analyst Blog

Positive news flowed in for Valeant Pharmaceuticals International, Inc. ( VRX) when the FDA approved its New Drug Application (NDA) for Jublia (efinaconazole 10% topical solution) for the treatment of ...
Pharmabiz

US FDA approves Valeant Pharma's Jublia to treat onychomycosis

Valeant Pharmaceuticals International, Inc., a multinational specialty pharmaceutical company, announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received ...
Business Insider

HUYABIO International And Tianjin Institute of Pharmaceutical Research Joint venture Submits Chinese New Drug Application For efinaconazole as Jublia™

SAN DIEGO, March 9, 2021 /PRNewswire/ -- HUYABIO International (HUYABIO), the leader in accelerating global development of China's pharmaceutical innovations, today announced that its joint venture ...